Isodiol International Inc. Share Price Canadian Securities Exchange
Equities
ISOL
CA46500L2003
Pharmaceuticals
Sales 2018 | 19.14M 26.15M 1.6B | Sales 2019 | 22.25M 30.41M 1.86B | Capitalization | 49.96M 68.28M 4.17B |
---|---|---|---|---|---|
Net income 2018 | -36M -49.2M -3.01B | Net income 2019 | -126M -172M -10.52B | EV / Sales 2018 | 12.6 x |
Net cash position 2018 | 15.55M 21.25M 1.3B | Net Debt 2019 | 5.22M 7.14M 436M | EV / Sales 2019 | 2.48 x |
P/E ratio 2018 |
-4.94
x | P/E ratio 2019 |
-0.37
x | Employees | - |
Yield 2018 * |
-
| Yield 2019 |
-
| Free-Float | 100% |
Managers | Title | Age | Since |
---|---|---|---|
Marcos Agramont
CEO | Chief Executive Officer | - | 24/17/24 |
Director/Board Member | - | 30/18/30 | |
Kevin Swadish
PRN | Corporate Officer/Principal | - | 14/19/14 |
Members of the board | Title | Age | Since |
---|---|---|---|
Marcos Agramont
CEO | Chief Executive Officer | - | 24/17/24 |
Director/Board Member | - | 30/18/30 | |
Director/Board Member | - | 21/18/21 |
1st Jan change | Capi. | |
---|---|---|
+43.17% | 6.29B | |
-14.69% | 4.55B | |
-8.17% | 3.23B | |
+6.95% | 3.27B | |
-1.76% | 2.56B | |
+50.20% | 2B | |
-7.85% | 1.68B | |
-0.40% | 1.64B | |
-9.91% | 1.59B |